Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

Overview of attention for article published in Clinical Cancer Research, March 2020

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (91st percentile)
High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

news: 2 news outlets
twitter: 7 X users

patent: 4 patents
guideline: 1 clinical guideline source

Readers on

mendeley: 122 Mendeley

So far, Altmetric has seen 9 X posts from 7 X users, with an upper bound of 139,923 followers.

I see myself as a teacher. It is always great to see one of your kids graduate and get a job! Well done Tisotumab Vedotin! Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer https://t.co/7kpMcVx7uV

Open Access UCL Research: Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer https://t.co/LH8Lg6hMDe

Ensayo clínico de #tisotumab en #Cancercervical metastásico o recurrente.

RT @CCR_AACR: Phase 1/2 Study: Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer. https://t.co/cIbZOWwT9U https://t.co/dVenbRXPpu

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 5 additional X posts.